Megasphaera micronuciformis
DSM 17226
BACTERIA
How to read the following data (Example)
Name:
Megasphaera micronuciformis Marchandin et al. 2003
DSM No.:
17226, Type strain
Strain designation:
AIP 412.00
Other collection no.
or WDCM no.:
CCUG 45952,CIP 107280
Isolated from:
human, liver abscess
Country:
France
Paris
Date of sampling:
2000
Nagoya Protocol Restrictions:
France requires a benefit-sharing declaration for French genetic resources at the time of utilization, i.e., conducting research. France considers access to genetic resources when utilization begins and not when the initial collection of the material took place and applies to material both in-situ and ex-situ and users within and outside of France.
To comply with French law, you, the user need to make a Declaration regarding access to genetic resources and benefit-sharing arising from your non-commercial utilisation of genetic resources. The steps are the following:
1. File a declaration via the CERFA form n. 15786 (https://www.formulaires.service-public.fr/gf/getAnnexe.do?cerfaAnnexe=1&cerfaFormulaire=15786*02) or by electronic procedure (https://www.demarches-simplifiees.fr/commencer/apa-declaration-pmorale)
2. Await approval by the Ministry for the Ecological Transition, the competent national authority
3. Respond to any requests for more information from the competent national authority
4. Receive an acknowledgment of receipt by the competent national authority certifying the prior informed consent (PIC) and establishment of mutually agreed terms (MAT) regarding benefit-sharing. This procedure shall not exceed 2 months.
For more information about this topic please see the Access and Benefit-Sharing Clearing House: https://absch.cbd.int/en/countries/FR
For more information about the commercial use of this genetic resources please contact: justiziariat@dsmz.de
History:
<- CCUG <- CIP <- JP Carlier, Institue Pasteur AIP 412.00
Cultivation conditions:
Medium 693
or
Medium 104 + fructose (2 g/L), anaerobic, 37°C
or
Medium 11b , anaerobic, 37°C
for reactivation on agar plates, distribute the complete content of the ampoule on one agar plate
Incubation time: 2-3 days
Please follow special instructions: 'Cultivation of Anaerobes'
Complete DSMZ Media List
Summary and
additional information:
<- CCUG <- CIP <- JP Carlier, Institue Pasteur AIP 412.00. Human, liver abscess; France, Paris. Type strain. Taxonomy/description (8816). Sequence accession no. AF473833 (8816). (Medium 693 or Medium 104 + fructose (2 g/L), 37°C, anaerobic or Medium 11b, 37°C, anaerobic). For reactivation on agar plates, distribute the complete content of the ampoule on one agar plate.
Literature:
8816
Risk group:
1 (+) (classification according to German TRBA)
Supplied as:
Delivery form Prices
DSM17226
DSM 17226
BACTERIA
How to read the following data (Example)
Name:
Megasphaera micronuciformis Marchandin et al. 2003
DSM No.:
17226, Type strain
Strain designation:
AIP 412.00
Other collection no.
or WDCM no.:
CCUG 45952,CIP 107280
Isolated from:
human, liver abscess
Country:
France
Paris
Date of sampling:
2000
Nagoya Protocol Restrictions:
France requires a benefit-sharing declaration for French genetic resources at the time of utilization, i.e., conducting research. France considers access to genetic resources when utilization begins and not when the initial collection of the material took place and applies to material both in-situ and ex-situ and users within and outside of France.
To comply with French law, you, the user need to make a Declaration regarding access to genetic resources and benefit-sharing arising from your non-commercial utilisation of genetic resources. The steps are the following:
1. File a declaration via the CERFA form n. 15786 (https://www.formulaires.service-public.fr/gf/getAnnexe.do?cerfaAnnexe=1&cerfaFormulaire=15786*02) or by electronic procedure (https://www.demarches-simplifiees.fr/commencer/apa-declaration-pmorale)
2. Await approval by the Ministry for the Ecological Transition, the competent national authority
3. Respond to any requests for more information from the competent national authority
4. Receive an acknowledgment of receipt by the competent national authority certifying the prior informed consent (PIC) and establishment of mutually agreed terms (MAT) regarding benefit-sharing. This procedure shall not exceed 2 months.
For more information about this topic please see the Access and Benefit-Sharing Clearing House: https://absch.cbd.int/en/countries/FR
For more information about the commercial use of this genetic resources please contact: justiziariat@dsmz.de
History:
<- CCUG <- CIP <- JP Carlier, Institue Pasteur AIP 412.00
Cultivation conditions:
Medium 693
or
Medium 104 + fructose (2 g/L), anaerobic, 37°C
or
Medium 11b , anaerobic, 37°C
for reactivation on agar plates, distribute the complete content of the ampoule on one agar plate
Incubation time: 2-3 days
Please follow special instructions: 'Cultivation of Anaerobes'
Complete DSMZ Media List
Summary and
additional information:
<- CCUG <- CIP <- JP Carlier, Institue Pasteur AIP 412.00. Human, liver abscess; France, Paris. Type strain. Taxonomy/description (8816). Sequence accession no. AF473833 (8816). (Medium 693 or Medium 104 + fructose (2 g/L), 37°C, anaerobic or Medium 11b, 37°C, anaerobic). For reactivation on agar plates, distribute the complete content of the ampoule on one agar plate.
Literature:
8816
Risk group:
1 (+) (classification according to German TRBA)
Supplied as:
Delivery form Prices
DSM17226
